Bert van Meurs Shares the New Late-breaking Results from the iMODERN Trial
Bert van Meurs, Chief Business Leader Image Guided Therapy and Member of the Executive Committee at Royal Philips, shared on LinkedIn:
”New late-breaking results from the iMODERN trial, presented at TCT 2025, bring important clarity for heart attack patients with multi-vessel disease.
This global study confirms that treating additional lesions during the initial procedure is just as safe as waiting to stage treatment, giving clinicians more flexibility to tailor care to each patient’s needs.
Complementary findings from the ILIAS ANOCA study also highlight the value of physiology-guided assessment and personalized therapy for patients with angina but no obstructive coronary arteries, resulting in sustained improvements in quality of life.
I’m proud that Philips solutions supported both of these impactful studies.
Together with our clinical partners, we’re helping advance evidence-based, individualized cardiovascular care for patients worldwide.”
Read the full announcement here.
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 8, 2026, 15:0310 Posts Not to Miss This Week
-
Nov 8, 2026, 14:55Andra T.: Antiphospholipid Syndrome and Its Thrombotic Risks
-
Nov 8, 2026, 14:06Shayan Mohammadmoradi: ZEUS Trial-Inflammation Reduction Without Fewer Cardiovascular Events
-
Nov 8, 2026, 14:05Kausik Ray: Plaque-Guided Care for Better Coronary Outcomes
-
Nov 8, 2026, 14:05Athira Elssa Johnson: Understanding Coronary Thrombosis and Its Risks
-
Nov 8, 2026, 14:04Sanjiv Beri: Blood Type Compatibility and the Balance of Giving and Receiving
-
Nov 8, 2026, 14:02Gabriela Hobbs: Recognizing Outstanding Abstract Achievements-ASH 2026
-
Nov 8, 2026, 12:22Marc Carrier: Advancing Catheter-Related Thrombosis Prevention Through Factor XI Inhibition
-
Nov 8, 2026, 11:56Why Genetic Predisposition Does Not Always Lead to Thrombosis – Stork Genetics